Rapid Identification of MINOCA Based on Novel Biomarkers

NCT04974320 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2616

Last updated 2021-07-23

No results posted yet for this study

Summary

Among the patients diagnosed as acute myocardial infarction by coronary angiography, 5%-25% of the patients did not find coronary artery obstructive lesions. These patients do not need PCI. The discovery and verification of clinical protocols for accurate identification of myocardial infarction in the absence of obstructive coronary artery disease(MINOCA)is a major issue that needs to be addressed.Novel biomarkers like grow stimulation expressed gene 2(ST2)can indicate the degree of coronary artery obstruction, copeptin is a biomarker of cardiac emergency state. No clinical studies have been conducted to evaluate whether the novel biomarkers combination regimen can diagnose or exclude MINOCA.

Our research aims to establish and validate a model for the recognition of MINOCA based on novel biomarkers (ST2, copeptin) and to evaluate the prognostic value of novel biomarkers among patients with acute chest pain.

Conditions

  • Myocardial Infarction With Non-obstructive Coronary Arteries
  • Grow Stimulation Expressed Gene 2
  • Copeptin
  • Identification
  • Prognosis

Interventions

BIOLOGICAL

blood biomarkers

All patients were obtained blood biomarkers: troponin, ST2, copeptin

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Jiali Wang, PhD,MD · Qilu Hospital, Shandong University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-05
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974320 on ClinicalTrials.gov